Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus SOLU MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus SOLU MEDROL.
CORTIFOAM vs SOLU-MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses inflammatory cytokines and immune cell activity.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
IV or IM: 10-40 mg methylprednisolone (as sodium succinate) every 4-6 hours; high-dose pulse therapy: 30 mg/kg IV over 30-60 minutes every 4-6 hours for 48-72 hours.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life: 2.5–3.5 hours. In clinical context, the biologic half-life (suppression of HPA axis) is longer (24–36 hours) due to tissue retention of active metabolites.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal: approximately 80% as metabolites (glucuronide and sulfate conjugates) and unchanged drug; biliary/fecal: less than 5%.
Category C
Category C
Corticosteroid
Corticosteroid